Sunday 11 October 2026 Export all VXRT data to Excel Powerpack

VAXART, INC.

VXRT Healthcare Biotechnology

VAXART, INC.’s revenue for fiscal 2025 (year ended December 2025) was $237.3 million, up 726.7% from fiscal 2024. In the quarter to June 2026, revenue fell 31.6%, EPS grew 14.3% and free cash flow grew 117.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

0.43 0.00 0.00%
Market cap
$92.4M
P/E
2.8×
Fwd P/E
2.1×
Dividend yield
—
F-score
6/9
Altman Z
−1.06
Beneish M
3.73
Dividend safety
n/a
Jun '17 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
— — — 4 4 3 2 3 4 6
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.83
Altman Z-Score
(6.02) (30.97) (5.27) (5.09) 9.29 11.97 (3.10) (7.29) (4.57) (1.06)
P/S ratio
0.12 2.68 2.86 0.77 124.61 853.72 315.02 11.97 4.65 0.34
Altman Z″-Score (non-manufacturers)
(11.45) (74.58) (11.39) (11.08) 4.95 5.11 (5.78) (16.58) (12.33) (4.73)
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 10.64
Beneish M-Score
— — 24.45 (2.02) (4.85) (4.03) (4.48) 58.85 (1.09) 3.73
P/Operating CF
(0.57) (14.81) (2.08) (1.99) (46.83) (48.15) (4.12) (6.53) (18.16) 2.63
P/B ratio
0.05 0.00 1.06 0.58 4.09 4.06 1.09 1.53 2.26 0.92
Price to Tangible BV
0.05 0.00 0.00 0.00 4.67 4.42 1.19 1.80 2.62 1.00
EV/Sales
(4.65) 7.28 0.56 (0.49) 93.54 668.39 66.88 6.75 2.89 0.08
EV/EBITDA
3.45 0.00 0.00 0.39 0.00 0.00 0.00 0.00 0.00 0.68
EV/Operating CF
1.46 (6.15) (0.16) 0.37 (15.94) (9.96) (0.27) (0.71) (1.85) 2.33
EV/FCF
1.46 (6.12) (0.15) 0.34 (15.16) (9.17) (0.24) (0.69) (1.83) 2.37
Quick Ratio
6.64 0.80 1.78 1.87 10.81 15.45 5.34 3.11 0.70 1.33
Current Ratio
6.76 0.83 1.96 1.92 10.93 15.69 5.55 3.32 0.75 1.57
Net Debt/EBITDA
1.41 (3.77) 0.52 1.11 4.62 2.43 0.88 0.53 0.89 (2.42)
Debt/Assets
0.25% 856.11% 5.52% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.01 (1.00) 0.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Asset Turnover
0.16 0.26 0.21 0.27 0.04 0.00 0.00 0.06 0.22 1.35
Operating CF/Net income
1.02 0.81 0.79 0.70 0.74 0.85 0.88 0.85 0.67 0.47
Capex/Depreciation
0.00 (0.09) (0.22) (0.24) (0.45) (1.20) (1.70) (0.22) (0.07) (0.02)
Interest Coverage
(15.28) (3.30) (8.12) (6.61) (16.10) (49.16) (87.81) (57.60) (22.33) 6.40
ROE
(90.60%) 124.46% 133.50% (154.15%) (47.26%) (45.33%) (72.29%) (97.94%) (114.71%) 22.26%
ROA
(52.13%) (55.85%) (92.31%) (51.61%) (33.98%) (37.71%) (57.47%) (67.13%) (51.85%) 9.26%
ROIC
0.00% 0.00% (811.31%) 0.00% 0.00% (216.07%) (481.30%) (287.93%) (575.30%) 47.09%
Return on Tangible Assets
(85.96%) 31,150.00% (222.75%) (215.95%) (27.25%) (42.71%) (110.96%) (189.39%) 481.19% 29.79%
Average Days of Receivables
24.61 39.38 157.62 133.94 30.13 29.05 68.22 148.79 152.22 78.99
Research and Development Expense of Revenue
317.98% 211.59% 415.36% 147.43% 490.93% 5,465.13% 75,751.40% 923.46% 258.58% 84.96%
Selling, General and Administrative Expense of Revenue
89.89% 59.92% 160.64% 62.74% 375.73% 2,454.04% 27,463.55% 306.06% 72.40% 7.42%
Intangible Assets out of Total Assets
0.00 0.01 0.55 0.46 0.10 0.07 0.06 0.10 0.05 0.04
Share Based Compensation of Revenue
21.35% 8.17% 12.96% 6.36% 107.71% 994.06% 12,698.13% 191.52% 40.07% 3.50%
Graham Net Nets
18.50 (1.89) (0.79) (0.86) 0.20 0.18 0.47 0.13 (0.29) 0.47
Graham Number
0.00 36.56 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.72
Earnings Yield
(113.45%) (90.75%) (122.87%) (291.43%) (6.13%) (9.25%) (89.36%) (95.08%) (51.52%) 17.14%
Free Cash Flow Yield
(2,561.52%) (44.31%) (128.47%) (184.65%) (4.95%) (8.53%) (86.97%) (81.73%) (33.97%) 9.40%
Revenue per Share
2.53 42.93 0.66 0.46 0.05 0.01 0.00 0.05 0.14 1.03
Operating CF per Share
(8.54) (73.82) (2.30) (0.61) (0.27) (0.49) (0.74) (0.49) (0.22) 0.03
Capex per Share
0.00 (0.35) (0.11) (0.04) (0.01) (0.04) (0.08) (0.01) 0.00 0.00
Free Cash Flow per Share
(8.54) (74.17) (2.42) (0.65) (0.28) (0.54) (0.82) (0.50) (0.22) 0.03
Cash per Share
10.99 21.96 1.82 0.63 1.44 1.37 0.75 0.27 0.26 0.28
Shareholders Equity per Share
5.32 (284.72) 1.78 0.60 1.40 1.54 0.87 0.40 0.29 0.38
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
5.32 (284.72) 1.78 0.60 1.40 1.54 0.87 0.40 0.29 0.38
Free Cash Flow
(30.00) (10.09) (15.25) (13.94) (24.97) (64.99) (104.38) (72.20) (45.32) 7.57
Working Capital
34.00 (0.77) 7.17 8.42 116.77 158.38 81.53 31.81 (22.62) 49.37
Capital Expenditures
— (0.05) (0.71) (0.85) (1.22) (5.16) (9.60) (1.75) (0.55) (0.14)
Net Current Asset Value
18.50 (39.49) (9.34) (6.48) 99.35 135.53 56.20 11.51 (39.20) 37.84
EV/EBIT
1.86 0.00 0.00 0.30 0.00 0.00 0.00 0.00 0.00 0.99
Capex to Sales
0.00 0.01 0.17 0.09 0.30 5.78 89.73 0.24 0.02 0.00
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.46
Other line items
Depreciation/Fixed assets
0.50 0.75 3.02 17.12 1.83 0.65 0.36 0.68 0.93 1.53
Cash ROIC
(52.26%) (337.81%) (61.79%) (52.65%) (9.98%) (18.36%) (50.59%) (74.04%) (40.96%) 5.00%
Accounts Receivable Turnover
13.69 9.49 3.43 3.64 2.05 4.40 2.35 4.87 3.83 7.49
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
— — — — — — 0.00 — — —
Average Days of Payables
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days of Inventory on Hand
— — — — — — 0.00 — — —
Average Receivables
0.65 0.62 1.21 2.71 1.98 0.20 0.05 1.51 7.49 31.66
Average Payables
2.65 1.40 1.18 0.91 1.49 3.00 4.69 3.55 4.27 14.23
Average Assets
56.40 22.31 19.88 36.13 94.81 186.88 187.51 122.84 129.11 176.23
Average Common Equity
32.45 (10.01) (13.74) 12.10 68.18 155.47 149.06 84.20 58.37 73.36

Fold the line items

Columns are period end dates